Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancer.

Scientific reports - 16 Jun 2022

Vlaar Judith M, Borgman Anouska, Kalkhoven Eric, Westland Denise, Besselink Nicolle, Shale Charles, Faltas Bishoy M, Priestley Peter, Kuijk Ewart, Cuppen Edwin

Abstract excerpt

Bladder cancer has a high recurrence rate and low survival of advanced stage patients. Few genetic drivers of bladder cancer have thus far been identified. We performed in-depth structural variant analysis on whole-genome sequencing data of 206 metastasized urinary tract cancers. In ~ 10% of the patients, we identified recurrent in-frame deletions of exons 8 and 9 in the aryl hydrocarbon receptor gene (AHRΔe8-9),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Exons
Share to Ligands

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Receptors, Aryl Hydrocarbon

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 35710704
DOI: 10.1038/s41598-022-14256-0
PMCID: PMC9203531

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancer.PMID 35710704Read ↗

Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancerSemantic proximity Read ↗

Recurrent exon-deleting activating mutations in <i>AHR</i> act as drivers of urinary tract cancerSemantic proximity Read ↗

Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics.Semantic proximity Read ↗

Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy.Semantic proximity Read ↗

Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer.Semantic proximity Read ↗

Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor Genomics.Semantic proximity Read ↗

Epidemiological Trends and Germline Variant Analysis of Young-Onset Bladder Cancer.Semantic proximity Read ↗

Clinical Exome Gene Panel Analysis of a Cohort of Urothelial Bladder Cancer Patients from Sri Lanka.Semantic proximity Read ↗

Novel variants in MLL confer to bladder cancer recurrence identified by whole-exome sequencing.Semantic proximity Read ↗

In-depth investigation of the molecular pathogenesis of bladder cancer in a unique 26-year old patient with extensive multifocal disease: a case report.Semantic proximity Read ↗

FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.Semantic proximity Read ↗

Single-cell Sequencing Reveals Variants in ARID1A, GPRC5A and MLL2 Driving Self-renewal of Human Bladder Cancer Stem Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.